SecBot SecBot
8-K ·Filed Nov 5, 2026

CAH

CARDINAL HEALTH INC
BULLISH
Impact 6/10
Horizonmonths Processed6d 14h ago SEC0000721371-26-000042
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised FY2027 guidance (+$0.40 midpoint) and strong Q1 beat signal operational momentum, particularly in the core Pharma segment. Watch for the CVS Health contract renewal finalization and the closing of the AdaptHealth Diabetes acquisition in Q3, which could further support the raised outlook.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$267.82
T+0 close · Nov 5, 2026 · via day close
Latest settled
+1.46%
T+1 · $271.72
vs SPY
+1.14%
α at T+1
Next horizon
T+5
in 10h
  1. T+0 · Nov 5 $267.82entry
  2. T+1 · 6d ago +1.46%α +1.14% · $271.72
  3. T+4 · todayOpen
  4. T+5 · in 10h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

REPLAYWatch the reaction play out
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cardinal Health reported Q1 FY2027 non-GAAP EPS of $3.26, beating the $2.94 consensus by 10.9%, and revenue of $67.5B vs $66.51B consensus. The company raised its FY2027 non-GAAP EPS guidance to $12.80-$13.00 from $12.40-$12.60, driven by strong Pharmaceutical & Specialty Solutions segment profit growth of 17% and a lower share count from $500M in Q1 buybacks.

Key Financial Metrics

EPS (Adj.)
$3.26
est $2.94 · +10.9% · GAAP: $2.38
Revenue
$67.5B
est $66.5B · +1.5% · +5.5% YoY
Rating
beat
Free Cash Flow
$1.6B
Gross Margin
3.85%

Key Facts

  • Q1 FY2027 revenue $67.5B, +5% YoY
  • GAAP diluted EPS $2.38, +27% YoY
  • Non-GAAP diluted EPS $3.26, +28% YoY, beat consensus of $2.94 by 10.9%
  • Pharmaceutical & Specialty Solutions segment profit +17% to $783M
  • Global Medical Products & Distribution segment profit fell 28% to $33M
  • FY2027 non-GAAP EPS guidance raised to $12.80-$13.00 from $12.40-$12.60
  • Completed $500M share repurchase in Q1; diluted share count guidance lowered to 231M-232M
  • Entered binding LOI to renew distribution agreements with CVS Health
  • Operating cash flow $1.398B vs $973M a year ago; adjusted free cash flow $1.583B

Financial Impact

Non-GAAP EPS beat consensus by $0.32 (10.9%); guidance raised by $0.40 at midpoint; $500M share repurchase completed

revenueepsguidanceshare countoperating cash flow

Segment Breakdown

SegmentRevenueGrowth
Pharmaceutical and Specialty Solutions$62.6B+5.7%
Global Medical Products and Distribution$3.2B+0.2%
Other$1.8B+7.5%

Risk Factors

  • GMPD segment profit declined 28% YoY, driven by unfavorable distribution and FX impacts
  • Guidance relies on lower share count from buybacks, which may not recur at the same pace
  • Tariff and geopolitical risks (Iran conflict) cited in forward-looking statements

Market Snapshot

Exchange
NYSE
Sector
Wholesale-Drugs, Proprietaries & Druggists' Sundries
Analyst Consensus
86% bullish (22 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000721371-26-000042
Document: cah-20261105.htm0000721371-26-000042
Document: 0000721371-26-000042-index-headers.html0000721371-26-000042
Document: 0000721371-26-000042-index.html0000721371-26-000042
Document: 0000721371-26-000042.txt0000721371-26-000042
8-K Data (Synthetic)0000721371-26-000042

Track record

15 reports on CAH

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 11, 2026today Press Release Neutral 2/10 Entry $277.45 Now $276.79 −0.24% settles Nov 13
  2. Nov 5, 20266d ago 8-K Bullish 6/10 Viewing Entry $267.82 to $271.72 Now $276.79 +3.35% ▲ +1.46% +1.14% vs SPY
  3. Oct 29, 202613d ago Institutional Cluster Neutral 2/10 Entry $251.09 to $250.48 Now $276.79 +10.24% ▼ −0.24% +1.53% vs SPY
  4. Oct 27, 202615d ago Institutional Cluster Mixed 3/10 Entry $244.76 to $251.09 Now $276.79 +13.09% ▲ +2.59% +2.97% vs SPY
  5. Oct 27, 202616d ago GOVT-CONTRACT Neutral 4/10 Entry $244.76 to $251.09 Now $276.79 +13.09% ▲ +2.59% +2.97% vs SPY
  6. Oct 1, 20265w ago 8-K Neutral 5/10 Entry $230.09 to $228.30 Now $276.79 +20.30% ▼ −0.78% −1.52% vs SPY
  7. Oct 1, 20265w ago Press Release Neutral 1/10 Entry $230.09 to $228.30 Now $276.79 +20.30% ▼ −0.78% −1.52% vs SPY
  8. Aug 20, 202611w ago Insider Cluster Neutral 4/10 Entry $228.46 to $229.51 Now $276.79 +21.15% ▲ +0.46% +0.05% vs SPY
  9. Aug 20, 202611w ago Insider Cluster Neutral 3/10 Entry $228.46 to $229.51 Now $276.79 +21.15% ▲ +0.46% +0.05% vs SPY
  10. Aug 20, 202611w ago Insider Cluster Neutral 4/10 Entry $228.46 to $229.51 Now $276.79 +21.15% ▲ +0.46% +0.05% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Fri (12h 14m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026